SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/D48A4B4D823CC7EC8AFE17C08CAE2E7506E19B0B5E4A891589A89F31DD8EB82ACE3D5DC5CC12CAB487E3EE8B24F97E65>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/D48A4B4D823CC7EC8AFE17C08CAE2E7506E19B0B5E4A891589A89F31DD8EB82ACE3D5DC5CC12CAB487E3EE8B24F97E65
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/D48A4B4D823CC7EC8AFE17C08CAE2E7506E19B0B5E4A891589A89F31DD8EB82ACE3D5DC5CC12CAB487E3EE8B24F97E65
http://www.w3.org/2000/01/rdf-schema#comment
"Results find that the rate of circulated tumor cells (CTC)-CEACAM5 positive (pos) increased with the increase of the stages in breast tumors. Patients with decreased CEACAM5 mRNA along with that of KRT19 have better prognosis."
xsd:string
http://purl.uniprot.org/uniprot/#_0F4D73C4F5E0A60CD6DDC67F92EA4B7E5785D0D8DA902B8E01A10DB171EED86E4DB593041803B34B6632D9647E26B8C5
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/D48A4B4D823CC7EC8AFE17C08CAE2E7506E19B0B5E4A891589A89F31DD8EB82ACE3D5DC5CC12CAB487E3EE8B24F97E65
http://purl.uniprot.org/uniprot/Q53G30
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/D48A4B4D823CC7EC8AFE17C08CAE2E7506E19B0B5E4A891589A89F31DD8EB82ACE3D5DC5CC12CAB487E3EE8B24F97E65
http://purl.uniprot.org/uniprot/#_Q53G30-mappedCitation-30535933
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/D48A4B4D823CC7EC8AFE17C08CAE2E7506E19B0B5E4A891589A89F31DD8EB82ACE3D5DC5CC12CAB487E3EE8B24F97E65